Crucell « Terug naar discussie overzicht

Draadje varkensgriep

1.005 Posts, Pagina: « 1 2 3 4 5 6 ... 26 27 28 29 30 31 32 33 34 35 36 ... 47 48 49 50 51 » | Laatste
flosz
0
Der neue H1N1(Schweinegrippe)-Impfstoff wird von der Firma Novartis hergestelltwerden. Dieser wird wahrscheinlich auf PER.C6 Zellen (menschlicheNetzhautzellen) gezüchtet werden und enthält MF-59, ein potenziell„schwächendes“ Hilfsmittel.

MF-59 ist ein auf Öl basierendes Hilfsmittel welches primär aus Squalene (in Haiausscheidungen und Haileber befindliches Fett), Tween80 und Span-85 besteht.
blog.hiphop.de/entry.php?u=offbeat&e_...

Hold a chicken in the air, stick a deck chair up your nose...
www.youtube.com/watch?v=3vUVJsfG3eA
Bijlage:
B_B
2
WHO says new flu "unstoppable", calls for vaccine
Posted by Desta Bishu | July 26th, 2009 at 1:23 pm |

Saying the new H1N1 virus is "unstoppable", the World Health Organization gave drug makers a full go-ahead to manufacture vaccines against the pandemic influenza strain on Monday and said healthcare workers should be the first to get one.

Every country will need to vaccinate citizens against the swine flu virus and must choose who else would get priority after nurses, doctors and technicians, said Dr. Marie-Paule Kieny, WHO director of the Initiative for Vaccine Research.

Several reports showed the new virus attacks people differently than seasonal flu — affecting younger people, the severely obese and seemingly healthy adults, and causing disease deep in the lungs.

Kieny briefed reporters on the findings of the WHO's Strategic Advisory Group of Experts on Immunization, or SAGE. "The committee recognized that the H1N1 pandemic … is unstoppable and therefore that all countries need access to vaccine," Kieney said.

"The SAGE recognized first that healthcare workers should be immunized in all countries in order to retain a functional health system as the virus evolves," she added.

After that, each country should decide who is next in line, based on the virus's unusual behavior.

Seasonal influenza is deadly enough — each year it is involved in 250,000 to 500,000 deaths globally. But most are the elderly or those with some kind of chronic disease that makes them more vulnerable to flu, such as asthma.

ELDERLY ADVANTAGE

The elderly seem to have some extra immunity to this new H1N1, which is a mixture of two swine viruses, one of which also contains genetic material from birds and humans. It is a very distant cousin of the H1N1 virus that caused the 1918 pandemic that killed 50 million to 100 million people.

A study published in the journal Nature on Monday confirmed that the blood of people born before 1920 carries antibodies to the 1918 strain, suggesting their immune systems remember a childhood infection.

The work by Dr. Yoshihiro Kawaoka also supports other studies that this new H1N1 strain does not stay in the nose and throat, as do most seasonal viruses.

"The H1N1 virus replicates significantly better in the lungs," Kawaoka said. Other studies have also shown it can cause gastrointestinal effects, and that it targets people not usually thought of as being at high risk.

"Obesity has been observed to be one of the risk factors for more severe reaction to H1N1? — something never before seen, Kieny added. It is not clear if obese people may have undiagnosed health problems that make them susceptible, or if obesity in and of itself is a risk.

On Friday, a team at the U.S. Centers for Disease Control and Prevention and the University of Michigan reported that nine out of 10 patients treated in an intensive care unit there were obese. They also had unusual symptoms such as blood clots in the lungs and multiple organ failure.

None have recovered and three died. The CDC estimates at least a million people are infected in the United States alone and clinics everywhere are advised not to test each and every patient, so keeping an accurate count of cases will be impossible. The United States has documented 211 deaths and WHO counted 429 early last week.

Kieny said WHO would also work to get better viruses for companies from which to make vaccines. She said the strains that had been distributed did not grow very well in chicken eggs — used to make all flu vaccines.

One exception — AstraZeneca's MedImmune unit makes a live virus vaccine that is squirted up the nose and it is easier to produce, Kieny said.

WHO said countries should continue with their normal vaccination programs against seasonal flu. Kieny said the seasonal H3N2 strain was also very active now in the southern hemisphere's winter.

Sanofi-Aventis, Novartis, Baxter, Schering-Plough's Nobilon, GlaxoSmithKline, Solvay, CSL and AstraZeneca's MedImmune are among those working on flu vaccines.

...the strains that had been distributed did not grow very well in chicken eggs...

www.ethiopianreview.com/articles/18165



aossa
0
quote:

B_B schreef:

[quote=aossa]
"ethiopianreview"
Hoe betrouwbaar is deze bron?
[/quote]
www.reuters.com/article/topNews/idUST...
OK, artikel daterend van 14 juli dus.
flosz
0
quote:

aossa schreef:

OK, artikel daterend van 14 juli dus.

Zie o.a. ook post Gert50 - 13 jul 09, 19:56 op pagina 54.
pardon
0
Login My Profile Logout Top News
Reuters top ten news stories delivered to your inbox each day.

SubscribeYou are here: Home > News > Article Home
Business & Finance
News
U.S.
Politics
International
Technology
Entertainment
Sports
Lifestyle
Oddly Enough
Health
Science
Special Coverage
Video
Pictures
Your View
The Great Debate
Blogs
Weather
Reader Feedback
Do More With Reuters
RSS
Widgets
Mobile
Podcasts
Newsletters
Your View
Make Reuters My Homepage
Partner Services
CareerBuilder
Affiliate Network
Professional Products
Support (Customer Zone)
Reuters Media
Financial Products
About Thomson ReutersWHO says new flu "unstoppable", calls for vaccine
Tue Jul 14, 2009 9:49am EDT
Email | Print | Share| Reprints | Single Page[-] Text [+]
1 of 8Full SizeRelated News
U.S. to spend $884 million more on swine flu vaccine
13 Jul 2009By Maggie Fox, Health and Science Editor
WASHINGTON (Reuters) - Saying the new H1N1 virus is "unstoppable", the World Health Organization gave drug makers a full go-ahead to manufacture vaccines against the pandemic influenza strain on Monday and said healthcare workers should be the first to get one.

Every country will need to vaccinate citizens against the swine flu virus and must choose who else would get priority after nurses, doctors and technicians, said Dr. Marie-Paule Kieny, WHO director of the Initiative for Vaccine Research.

Several reports showed the new virus attacks people differently than seasonal flu -- affecting younger people, the severely obese and seemingly healthy adults, and causing disease deep in the lungs.

Kieny briefed reporters on the findings of the WHO's Strategic Advisory Group of Experts on Immunization, or SAGE. "The committee recognized that the H1N1 pandemic ... is unstoppable and therefore that all countries need access to vaccine," Kieney said.

"The SAGE recognized first that healthcare workers should be immunized in all countries in order to retain a functional health system as the virus evolves," she added.

After that, each country should decide who is next in line, based on the virus's unusual behavior.

Seasonal influenza is deadly enough -- each year it is involved in 250,000 to 500,000 deaths globally. But most are the elderly or those with some kind of chronic disease that makes them more vulnerable to flu, such as asthma.

ELDERLY ADVANTAGE

The elderly seem to have some extra immunity to this new H1N1, which is a mixture of two swine viruses, one of which also contains genetic material from birds and humans. It is a very distant cousin of the H1N1 virus that caused the 1918 pandemic that killed 50 million to 100 million people.

A study published in the journal Nature on Monday confirmed that the blood of people born before 1920 carries antibodies to the 1918 strain, suggesting their immune systems remember a childhood infection.

The work by Dr. Yoshihiro Kawaoka also supports other studies that this new H1N1 strain does not stay in the nose and throat, as do most seasonal viruses.

"The H1N1 virus replicates significantly better in the lungs," Kawaoka said. Other studies have also shown it can cause gastrointestinal effects, and that it targets people not usually thought of as being at high risk.

"Obesity has been observed to be one of the risk factors for more severe reaction to H1N1" -- something never before seen, Kieny added. It is not clear if obese people may have undiagnosed health problems that make them susceptible, or if obesity in and of itself is a risk.

On Friday, a team at the U.S. Centers for Disease Control and Prevention and the University of Michigan reported that nine out of 10 patients treated in an intensive care unit there were obese. They also had unusual symptoms such as blood clots in the lungs and multiple organ failure
[verwijderd]
0
ma 27 jul 2009, 10:40

Prof: 'Griepalarm moet angst zaaien'

PARIJS - De Mexicaanse griep is niet gevaarlijk. En de wereldwijde mobilisatie tegen de pandemie dient geen ander doel dan het zaaien van angst. Althans, als we de Franse professor Bernard Debré moeten geloven.

Debré doet zijn uitspraken in een interview met de Franse zondagkrant Journal du Dimanche. "De griep is waarschijnlijk zelfs minder gevaarlijk dan de normale griep", zegt Debré, die in Frankrijk een bekende uroloog is en afgevaardigde voor de UMP-partij van Sarkozy.

"De zieken, bij wie men overigens niet eens nagaat of zij H1N1 hebben, wordt inmiddels gevraagd paracetamol te slikken". Debré legt de schuld bij de Wereldgezondheidsorganisatie WHO. "Overheden hadden geen andere keus dan dan drastisch op te treden, nadat de WHO met dagelijkse berichtgeving en talloze persconferenties zorgde voor een paniekgolf."

Bron: Telegraaf
[verwijderd]
0
@ Pardon.

Svp bij knippen en plakken de niet ter zake zijnde tekst eruit laten.

Dank

Dirk
flosz
0
quote:

Dirk R. Wijnen schreef:

@ Pardon.

Svp bij knippen en plakken de niet ter zake zijnde tekst eruit laten.

Dank

Dirk
En bronvermelding en svp niet honderdduuzend keer hetzelfde!
Maw: lezen ipv braken....
flosz
0
Sanofi H1N1 + TIV - Adults and Elderly
This study is not yet open for participant recruitment.
Verified by National Institute of Allergy and Infectious Diseases (NIAID), July 2009
First Received: July 21, 2009 Last Updated: July 23, 2009

The purpose of this study is to assess the safety and immune response (body's defense against disease) to an experimental H1N1 influenza vaccine against the 2009 H1N1 virus. This study will help determine how the H1N1 flu shot should be given with the seasonal flu shot to make it most effective. Participants will include up to 850 healthy adults, ages 18 and older. Participants will receive at least one H1N1 vaccine in addition to placebo and the seasonal flu shot over 3 study visits about 21 days apart. Study procedures include: medical history, physical exam, maintaining a memory aid, and blood sample collection. Participants will be involved in the study for about 8 months.
clinicaltrials.gov/show/NCT00943878

CSL H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations
This study is not yet open for participant recruitment.
Verified by National Institute of Allergy and Infectious Diseases (NIAID), July 2009
First Received: July 21, 2009 Last Updated: July 23, 2009

The purpose of this study is to assess the safety and immune response (body's defense against disease) to an experimental H1N1 influenza vaccine in healthy adult and elderly populations. The study will enroll up to 450 healthy adults ages 18 and older with no history of H1N1 infection or vaccination. Two hundred individuals will be 18-64 years old, and the other 200 will be greater than or equal to 65 years of age. Participants will be randomly assigned to 1 of 2 possible vaccine groups: group 1 will receive 15 mcg of H1N1 vaccine; group 2 will receive 30 mcg of H1N1 vaccine. Both groups will receive vaccine injections on days 0 and 21 in the arm muscle.
Study procedures include: medical history, physical exam, maintaining a memory aid, and blood sample collection.
Participants will be involved in study related procedures for approximately 7 months.
clinicaltrials.gov/show/NCT00943488

Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations
This study is not yet open for participant recruitment.
Verified by National Institute of Allergy and Infectious Diseases (NIAID), July 2009
First Received: July 21, 2009 Last Updated: July 23, 2009

The purpose of this study is to assess the safety and the body's immune response (body's defense against disease) to an experimental H1N1 influenza vaccine in healthy adult and elderly populations. The study will enroll up to 450 healthy adults ages 18 and older with no history of H1N1 infection or vaccination. Two hundred individuals will be 18-64 years old, and the other 200 will be greater than or equal to 65 years of age. Participants will be randomly assigned to 1 of 2 possible vaccine groups: group 1 will receive 15 mcg of H1N1 vaccine; group 2 will receive 30 mcg of H1N1 vaccine. Both groups will receive vaccine injections on days 0 and 21 in the arm muscle.
Study procedures include: medical history, physical exam, maintaining a memory aid, and blood sample collection.
Participants will be involved in study related procedures for approximately 7 months.
clinicaltrials.gov/show/NCT00943631
[verwijderd]
0
seekingalpha.com/article/151366-what-...

What's the Delay In Support for Vical?

In the chicken, egg and pig story, what is the delay in the Navy’s support for Vical’s (VICL) DNA based H1N1 swine flu vaccine?

Bloomberg’s “Swine Flu Vaccine Delays Won’t Slow October Timetable” and “First Trials of Swine Flu Vaccine Begin in Australia” report that the US has contracted with five pharmaceutical companies to stockpile swine flu (H1N1) vaccines: Novartis (NVS) 45%, Sanofi Aventis (SNY) 26%, CSL (CSL:AU) 19%, and AstraZeneca (AZN) and GlaxoSmithKline (GSK) the remainder. Of these suppliers, only Australian based CSL is ready to start clinical trials. The others are incurring delays caused by production inefficiencies.

All these companies say they will be ready to start shipping in October, but that conflicts with regular network news reports showing the virus stubbornly replicating too slowly on conveyor belts of chicken eggs. Maybe a real swine flu pandemic will force the government to finally break their addiction to traditional vaccine development and crack the egg for good.

The Wall Street Journal’s “Swine Flu Prevention Takes on New Urgency” reports that Sanofi, Novartis, Glaxo and CSL are only yielding 30% of the active ingredient typically produced with seasonal flu.

Vical’s DNA-based vaccine produced 100% protection in preclinical trials with 2 doses and 75% protection with 1 dose. Vical developed its vaccine within weeks of receiving samples and the genetic coding from the government under a Cooperative Research and Development Agreement (CRADA) with the U.S. Naval Medical Research Center [NMRC]. Vical is now waiting for funding from the Navy to begin clinical trials.

The key Vical difference is its vaccine is a DNA plasmid rather than a killed or weakened virus. Production cycles are measured in weeks rather than months, and Vical already has large scale cGMP manufacturing capability.

The Vical advantage seems to have been lost in the big money politics of vaccine stockpiling. But I believe that Vical could emerge a winner if a real swine flu pandemic emerges. No other company could develop inventory as quickly.

I also believe that Navy funding will be forthcoming. Just imagine a swine flu outbreak on an aircraft carrier. In Vical’s favor is that the NIH is already funding development of their RapidResponse(tm) DNA vaccine manufacturing platform.

Disclosure: Author is long VICL.
[verwijderd]
0
quote:

wpw schreef:

seekingalpha.com/article/151366-what-...

and crack the egg for good.

Quote of the year.

p.s. al moet ik zeggen dat de volgende ook wel leuk is ivm de recessie:
" bij laag water zie je pas wie er geen zwembroek aan hebben"
voda
0
Griep: feit en fictie
27 juli 2009, 12:00 | BNR.nl
Pers en politiek zitten er bovenop, maar het merendeel van de Nederlanders lijkt het niet te deren: de Mexicaanse griep.

Maar wat nou als het virus in rap tempo slachtoffers veroorzaakt? Dat is toch een angstbeeld, waar je liever niet aan denkt. Behalve dan in de bioscoop. Want in films zijn dodelijke virussen, die om zich heen grijpen altijd een geliefd thema, weet BNR redacteur Thomas Schuurman. Luister naar zijn bijdrage via onderstaande link.

Een beknopte chronologie van de verspreiding van het H1N1-virus in Nederland

Sinds 30 april zijn zeker 273 Nederlanders besmet geraakt met de Mexicaanse griep. Van hen kregen 73 mensen de griep zonder in het buitenland te zijn geweest.

21 juli: het aantal vastgestelde griepgevallen ligt op 211. Van hen raakten 65 mensen in Nederland besmet.

10 juli: het aantal griepgevallen ligt op 152, ruim een derde raakte in Nederland besmet.

21 juni: het aantal griepgevallen ligt op 102, waarvan 47 binnenlandse besmettingen.

18 juni: Nederland koopt 34 miljoen griepvaccins. Met deze hoeveelheid kunnen alle Nederlanders tweemaal een prikje krijgen. Hoe duur de aankoop was wil minister Ab Klink (Volksgezondheid) niet zeggen.

12 juni: een 39-jarige man wordt opgenomen in het Universitair Medisch Centrum in Groningen. Ruim een maand ligt de Mexicaanse grieppatiënt in quarantaine op de intensive care.

8 juni: de Mexicaanse griep blijkt in Nederland twee keer te zijn overgedragen van mens op mens. Dit zijn de eerste binnenlandse besmettingen; de meeste patiënten liepen het virus in het buitenland op.

30 april: eerste geval van Mexicaanse griep in Nederland wordt gemeld. Een 3-jarig kind heeft de ziekte onder de leden. Waarschijnlijk liep het de ziekte op in Mexico. Vanaf deze dag neemt het aantal besmettingen wekelijks toe. Ook maakt minister Klink op 30 april bekend dat Nederland bij de farmaceutische industrie een optie heeft genomen op 34 miljoen vaccins tegen Mexicaanse griep.

flosz
0
quote:

winx08 schreef:

" bij laag water zie je pas wie er geen zwembroek aan hebben"
vicl voor nu nog even watertrappelen, duiken binnenkort in de blote bips een leeg zwembad in....
Bijlage:
flosz
0
Vor acht Jahren kam ein viel versprechender Grippeimpfstoff in die Schlagzeilen, der anstatt mit der Spritze einfach in die Nase gesprüht wird. Das Problem war aber, dass er zu Gesichtslähmungen führte. Sind bei der Impfung des neuen Pandemie-Präparats im schlimmsten Fall dann zig Millionen Menschen plötzlich Versuchskaninchen?
bazonline.ch/wissen/medizin-und-psych...
[verwijderd]
0
AMERSFOORT - In Amersfoort is een griepteam opgericht om de Mexicaanse griep te lijf te gaan.

Een team dat bedrijven in heel Nederland wil helpen de griepepidemie door te komen. Het griepteam denkt daarbij vooral aan de komende winter, waarin volgens een prognose van het Rijksinstituut voor Volksgezondheid en Milieu mogelijk 30 procent van alle Nederlanders griep krijgen; drie keer zoveel als in een gewone winter.

Het griepteam bestaat vooralsnog uit vijf professionals met achtergronden in gezondheidszorg, crisismanagement, communicatie en financiën, zegt Natasja van Groningen, communicatiedeskundige en een van de initiatiefnemers. ,,We zullen uitleggen dat medewerkers met de eerste griepverschijnselen maar meteen thuis moeten gaan werken, zodat ze niemand op het werk besmetten. Dat thuiswerken moet dan wel mogelijk worden gemaakt met een goed uitgeruste laptop.’’

Als eenderde van het personeel uitvalt, moet een bedrijf kunnen blijven draaien. ,,Met bedrijven maken we een rampenplan op maat. Je moet van tevoren zorgen dat er voor alle belangrijke functies invallers zijn, en weten waar je kunt aankloppen als je mensen van buiten wilt aantrekken. Ook communicatie is daarbij van belang: je moet duidelijk maken, voor de eigen medewerkers en je klanten, dat het bedrijf blijft functioneren.’’

Het griepteam wil uit werknemers van elk bedrijf een eigen team samenstellen, dat in geval van nood in actie treedt. ,,Een team dat de bestaande situatie kent en ook de bevoegdheden krijgt om snel knopen door te hakken. Ons griepteam blijft op de achtergrond bereikbaar om ondersteuning te bieden.

www.ad.nl/amersfoort/3397003/Grieptea...
[verwijderd]
0
Proefkonijn voor griepvaccin gezocht AMSTERDAM - Er worden honderden Nederlanders gezocht die voor medicijnproducenten willen dienen als proefpersoon voor een nieuw vaccin tegen de Mexicaanse griep.

Het Zwitserse bedrijf Novartis, een van de twee leveranciers van de 34 miljoen Nederlandse inentingen, heeft opdracht gegeven komende maand in ons land te beginnen met een test van het vaccin, meldt het AD.

Het inenten van proefpersonen wordt gedaan door medische onderzoeksbureaus, die op zoek gaan naar gezonde volwassenen en kinderen.

'Weinig risico's'

Griepexpert Ab Osterhaus noemt de proef een 'goede zaak' en de risico's voor de proefpersonen klein. "Formeel moet ik zeggen dat er risico's zijn, omdat het om een test gaat. Maar de manier van het produceren van het vaccin is al grotendeels goedgekeurd", aldus de viroloog. "Groot voordeel voor een proefpersoon is dat je letterlijk vooraan in de rij staat."

Pas als de vaccins op mensen getest zijn en de uitkomsten goed zijn, krijgt een farmaceut toestemming om het medicijn op de markt te brengen.

www.telegraaf.nl/binnenland/4491695/_...
aossa
0
July 24, 2009

At Novartis, we are making good progress in our efforts to rapidly produce and commercialize a vaccine against the H1N1 virus. We started clinical trials with the H1N1 vaccine in July.

Novartis has started large-scale antigen production at all flu vaccines manufacturing sites in Europe, using both traditional egg-based manufacturing as well as its faster cell-based vaccine production capacity to maximize the potential vaccine supply. Using cell-culture technology, first batches were successfully produced from both the wild virus strain and the “reassortant seed” modified virus recommended by the WHO and health authorities. As reported by WHO, current yields from the reassortant strain are lower than expected. We are working diligently to make adjustments to improve the yields currently observed.

Novartis has secured several orders for H1N1 vaccines amid discussions with more than 35 governments. The US government has now awarded Novartis two contracts totaling USD 979 million for future purchase of H1N1 bulk vaccine and the Group’s proprietary MF59 adjuvant, while contracts have also been signed with other countries including France, the Netherlands and Switzerland.

Pending approval from Regulatory authorities and evolution of the yields, we expect deliveries to begin to government customers in the fourth quarter and continue into 2010.

www.novartis.com/newsroom/swine-flu/
1.005 Posts, Pagina: « 1 2 3 4 5 6 ... 26 27 28 29 30 31 32 33 34 35 36 ... 47 48 49 50 51 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

 AEX
901,28  -3,96  -0,44%  12:20
 Germany40^ 22.295,40 -1,09%
 BEL 20 4.311,71 -1,24%
 Europe50^ 5.288,45 -0,60%
 US30^ 41.826,80 -0,37%
 Nasd100^ 19.330,20 -0,54%
 US500^ 5.608,36 -0,41%
 Japan225^ 35.539,80 -0,48%
 Gold spot 3.129,60 +0,51%
 EUR/USD 1,0803 +0,08%
 WTI 70,90 -0,46%
#/^ Index indications calculated real time, zie disclaimer

Stijgers

Sif Holding +6,78%
Accsys +1,63%
HAVAS +1,06%
PostNL +1,06%
ACOMO +0,93%

Dalers

Avantium -16,02%
THEON INTERNAT -4,94%
CM.COM -2,76%
Philips Konin... -2,51%
ForFarmers -2,50%